Gioconda V Gallo-Etienne

Title: **Innovator Spotlight: Gioconda V Gallo-Etienne**

Introduction

Gioconda V Gallo-Etienne, based in Union, NJ, is a notable inventor with a focus on medicinal chemistry and pharmacological applications. She holds two patents that showcase her contributions to the field of pharmaceutical innovations.

Latest Patents

Her latest patents include the development of "Substituted imidazo[1,2-c]quinazolines as A2A antagonists." This invention discloses compounds designed to selectively antagonize A2A receptors, which are densely located in the basal ganglia. These compounds show potential for treating neurodegenerative diseases, such as Parkinson's disease, and managing movement disorders caused by medications for Parkinson's.

Another significant patent by Gallo-Etienne is for "Factor XIa inhibitors." This invention involves compounds that can treat or prevent conditions like thromboses, embolisms, and fibrotic changes. These compounds act as selective inhibitors of Factor XIa or dual inhibitors of Factor XIa alongside plasma kallikrein.

Career Highlights

Gioconda currently works at Merck Sharp & Dohme Corporation, a leading company in the pharmaceutical industry. Her role has allowed her to contribute significantly to innovative drug development processes that address critical health concerns.

Collaborations

In her professional journey, Gallo-Etienne collaborates with esteemed colleagues such as Yeon-Hee Lim and Zhuyan Guo. Their collective expertise enhances the impact of their research and innovations in the pharmaceutical sector.

Conclusion

Gioconda V Gallo-Etienne's work exemplifies the important intersection of innovation and healthcare. With her contributions through meaningful patents, she continues to drive advancements in treatments for challenging medical conditions, making a notable mark in the field of medicinal chemistry.